Korean J Pain.  2020 Oct;33(4):291-293. 10.3344/kjp.2020.33.4.291.

Chemotherapy-induced peripheral neuropathy: bench to clinical practice

• Kim E

• KMID: 2507134
• DOI: http://doi.org/10.3344/kjp.2020.33.4.291

Reference

1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, et al. 2019; Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 20:1493–505. DOI: 10.1016/S1470-2045(19)30456-5. PMID: 31521509. PMCID: PMC6838671.

2. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. 2013; Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 31:2699–707. DOI: 10.1200/JCO.2013.49.1514. PMID: 23775951.

3. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. 2014; Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 155:2461–70. DOI: 10.1016/j.pain.2014.09.020. PMID: 25261162.

4. Sisignano M, Baron R, Scholich K, Geisslinger G. 2014; Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. Nat Rev Neurol. 10:694–707. DOI: 10.1038/nrneurol.2014.211. PMID: 25366108. PMCID: PMC5991994.

5. Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. 2019; Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 25:6295–301. DOI: 10.1158/1078-0432.CCR-18-2152. PMID: 31123053. PMCID: PMC6825524.

6. Li Y, North RY, Rhines LD, Tatsui CE, Rao G, Edwards DD, et al. 2018; DRG voltage-gated sodium channel 1. 7 is upregulated in paclitaxel-induced neuropathy in rats and in humans with neuropathic pain. J Neurosci. 38:1124–36. DOI: 10.1523/JNEUROSCI.0899-17.2017. PMID: 29255002.

7. Bankar G, Goodchild SJ, Howard S, Nelkenbrecher K, Waldbrook M, Dourado M, et al. 2018; Selective NaV1. 7 antagonists with long residence time show improved efficacy against inflammatory and neuropathic pain. Cell Rep. 24:3133–45. DOI: 10.1016/j.celrep.2018.08.063. PMID: 30231997. PMCID: PMC7481244.

8. Poupon L, Lamoine S, Pereira V, Barriere DA, Lolignier S, Giraudet F, et al. 2018; Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology. 140:43–61. DOI: 10.1016/j.neuropharm.2018.07.026. PMID: 30056126.

9. Kim K, Jeong W, Jun IG, Park JY. 2020; Antiallodynic and anti-inflammatory effects of intrathecal R-PIA in a rat model of vincristine-induced peripheral neuropathy. Korean J Anesthesiol. doi: 10.4097/kja.19481. DOI: 10.4097/kja.19481. PMID: 32046474.

10. Flatters SJ, Bennett GJ. 2004; Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 109:150–61. DOI: 10.1016/j.pain.2004.01.029. PMID: 15082137.

11. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. 2014; Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 32:1941–67. DOI: 10.1200/JCO.2013.54.0914. PMID: 24733808.

12. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. 2013; Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 309:1359–67. DOI: 10.1001/jama.2013.2813. PMID: 23549581. PMCID: PMC3912515.

13. Fallon MT, Storey DJ, Krishan A, Weir CJ, Mitchell R, Fleetwood-Walker SM, et al. 2015; Cancer treatment-related neuropathic pain: proof of concept study with menthol--a TRPM8 agonist. Support Care Cancer. 23:2769–77. DOI: 10.1007/s00520-015-2642-8. PMID: 25680765. PMCID: PMC4519585.

14. Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, et al. 2019; Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 12:2039–52. DOI: 10.2147/JPR.S213912. PMID: 31308732. PMCID: PMC6613356.

15. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, et al. 2018; OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 128:816–25. DOI: 10.1172/JCI96160. PMID: 29337310. PMCID: PMC5785270.

16. Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, et al. 2018; Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med. 215:1301–13. DOI: 10.1084/jem.20170584. PMID: 29703731. PMCID: PMC5940258.

17. Kim E, Hwang SH, Kim HK, Abdi S, Kim HK. 2019; Losartan, an angiotensin II type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia. Mol Neurobiol. 56:7408–19. DOI: 10.1007/s12035-019-1616-0. PMID: 31037647.

18. Yin M, Kim YO, Choi JI, Jeong S, Yang SH, Bae HB, et al. 2020; Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy. Korean J Pain. 33:318–25. DOI: 10.3344/kjp.2020.33.4.318. PMID: 32989196.

19. Hait WN. 2005; Translating research into clinical practice: deliberations from the American Association for Cancer Research. Clin Cancer Res. 11:4275–7. DOI: 10.1158/1078-0432.CCR-05-0321. PMID: 15958606.